Tarsus Pharmaceuticals(NASDAQ) TARS

Tarsus Pharmaceuticals, Inc. makes eye drops that kill tiny eyelid mites. These parasites cause red and itchy eyes for many people. The company also develops pills to prevent tick-borne diseases.

What Tarsus Makes

• XDEMVY Eye Drops: First approved treatment targeting the mites that cause eyelid inflammation.
• TP-04 Gel: Investigational medicine designed to treat skin and eye redness from rosacea.
• TP-05 Oral Tablet: Experimental drug that kills ticks to stop Lyme disease transmission.
• IRX-101 Antiseptic: Eye solution meant to reduce pain after medical injections.
• Retinal Treatments: Late-stage oral pills being developed for inherited causes of blindness.

How the Company Grows

• Launched XDEMVY in Aug. 2023 to treat lid margin disease.
• Acquired iRenix Medical in July 2026 to expand into eye antiseptics.
• Entered an agreement to buy Alkeus Pharmaceuticals on July 31, 2026.
• Received a $15.0 million milestone payment for progress in China during 2026.
• Secured a $125.0 million private stock sale on Aug. 5, 2026.

A New Way to Kill Parasites

Tarsus uses a compound called lotilaner to paralyze parasites without harming human cells. This approach allows the company to treat specific infestations that previously lacked effective medical options.

The Financial Numbers

• Net product sales rose to $173.9 million in the second quarter of 2026, up more than 69% year over year.
• Total revenue reached $336.0 million for the six months ended June 30, 2026.
• Net loss was $18.6 million for the three months ended June 30, 2026.
• Cash and marketable securities totaled $449.7 million as of June 30, 2026.

Bottom Line

Tarsus has transitioned from a clinical-stage developer to a commercial pharmaceutical firm with a growing eye care and infectious disease pipeline. Its expansion into retinal health and tick-borne prophylaxis reflects a strategy of targeting high-need medical markets with novel chemical applications.